Cultured Human Cell Monolayers Cryopreserved In Situ

描述(由申请人提供)：蜂窝保存服务公司(CPSI)开发用于蜂窝系统低温存储的新方法。CPSI的策略是围绕细胞死亡级联反应背后的分子事件而设计的，这些分子事件是由于广泛的细胞压力而启动的。一旦知道，就可以开发出调节这些细胞死亡过程并提高细胞存活率的方法。CPSI的科学家S最近参与了一种新型低温保存介质(低温保存介质)的开发，再加上目前与保存介质公司(BioLife Solutions-CryoStor)和其他分发原代人体肝脏和皮肤细胞的生物技术公司的合作，促使CPSI对进一步探索原位冷冻方法和设备以批量冷冻(加工)含有人体细胞的多孔培养皿产生了兴趣。拟议的研究以CPSI的科学家自1990年代末以来一直致力于的方法和研究为基础？S。这项建议的目的是为了完成以下工作：SA1-确定用作原位冷冻保存溶液的最佳载体介质；SA2-测试一系列冷冻保护剂的混合物，以确定哪些提供最大的低温保护；SA3-测试不同的细胞黏附和培养基质的能力，以最大限度地提高解冻后人类细胞的黏附能力；SA4-测试专有细胞培养板以确定适合这一过程的候选者。SA5-确定最大限度提高细胞存活率的降温速度；SA6？比较原位保存的细胞和用传统悬浮技术保存的细胞的活性和功能。第二阶段将致力于扩大高通量筛选的流程(即384井板，在-80℃下存储一年)。CPSI计划在第三阶段将开发的技术授权给小型生物技术公司和大型制药行业。

DESCRIPTION (provided by applicant): Cell Preservation Services Inc (CPSI) develops new approached for low temperature storage of cellular system. CPSI's strategy is designed around the molecular events underlying cell death cascades that are launched due to extensive cell stress. Once known, methods are developed which modulate these cell death processes and improve cell survival. CPSI's scientist?s recent involvement in developing a new cryopreservation media (CryoStor), coupled with current associations with preservation media companies (BioLife Solutions - CryoStor) and other biotech companies who distribute primary human liver and skin cells, has precipitated CPSI's interest in further exploring in situ cryopreservation methodologies and devices to bulk freeze (process) multiwell dishes containing human cells. The proposed investigations build upon approaches and studies that current CPSI scientists have been working on since the late-1990?s. The intent of this proposal is to accomplish the following: SA1 - Identify the best carrier medium to use as the cryopreservation solution for in situ cryopreservation; SA2 - Test a cocktail of cryoprotective agents to determine those that confer the maximum cryoprotection; SA3 - Test different cell adhesion and culture matrices for their abilities to maximize the adhesion of human cells subsequent to thawing; SA4 - Test proprietary cell culture plates to identify suitable candidates for the process. SA5- Identify cooling rates that maximize cell survival; SA6 ? Compare cell viability and function in cells preserved in situ to those preserved using conventional suspended technology. Phase II will be dedicated to scaling up the process for high throughput screening (i.e. 384 well plates, one year storage time at -80C). CPSI plans to license the developed technology to both small biotechnology companies and large pharmaceutical industries in Phase III.